Introduction
Breast cancer accounts for a substantial proportion of the cancer burden in women, with an estimated 1.4 million new cases per year and more than 450,000 breast cancer-related deaths per year worldwide. 1 In Denmark, breast cancer accounted for 29% of all incident cancers and 16% of all cancer deaths among women in the period 1999-2003. 1 Despite increasing survival in the Nordic countries, Denmark still has a deficit compared with the other Nordic countries. In 2005-2007, Denmark had a 3.0% lower 1-year and 6.1% lower 5-year survival than Sweden. [2] [3] [4] Prompted by the general lower cancer survival in Denmark compared with neighboring countries, National Cancer Plans 
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Lietzen et al were introduced in 2002 and 2005, respectively, aiming to improve survival of cancer patients. 6 Breast cancer treatment in Denmark is standardized in programs formed by the Danish Breast Cancer Cooperative Group (DBCG). These programs have changed over the last decade towards a more widespread use of sentinel node technique and breast conserving surgery with adjuvant radiotherapy, 7 prolonged use of tamoxifen, and introduction of aromatase inhibitors. 8 Use of chemotherapy has improved with anthracyclines and/or taxanes, and most recently, in 2006, anti-HER2-therapy with trastuzumab according to the biomarker profile has been added to the programs. 8, 9 The beneficial effect of these treatments on survival has been documented in randomized controlled trials, 10, 11 and data from the DBCG database have, during the period 1977-2006, shown an increase in 5-year survival in Danish breast cancer patients from 65% to 81%. 12 A breast cancer mammographic screening program was introduced in 2007 and 2008 in the northern and central regions of Denmark, respectively and may influence survival. Numerous investigations have proven a 25%-30% increased survival after introduction of screening programs in other countries. [13] [14] [15] We used population-based registries in northern and central Denmark to examine changes in the mortality and survival of breast cancer patients of all ages between 1998 and 2009.
Material and methods
We conducted this study in the central and the northern Denmark regions, with a total population of 1.8 million persons. The National Health Service provides tax-supported health care for all inhabitants of Denmark, guaranteeing free treatment in hospitals. Virtually no breast cancer patients were treated in private hospitals during the study period. 16 
Identification of breast cancer patients
Through the Danish National Registry of Patients (DNRP), we identified all women resident in the northern or central regions of Denmark who had their first breast cancer diagnosis recorded in a hospital within one of the two regions over the period January 1, 1998 through December 31, 2009. The DNRP contains information about all admissions from nonpsychiatric hospitals in Denmark since 1977 and outpatient data from 1995. 17 This registry includes information on civil registration number, dates of admission and discharge, surgical procedure(s) performed, and up to 20 diagnoses from each hospital contact. Since 1994, diagnoses have been classified according to the International Classification of Diseases 10th edition (ICD-10). The ICD codes used to identify breast cancer were ICD-10 C50.x.
Survival
Since 1968, the Central Office of Civil Registration has assigned a unique 10-digit personal identification number to all Danish citizens. 18 This number, unique to each Danish resident, is used in all Danish registries, allowing unambiguous individual-level data linkage. From the Civil Registration System we also obtained information on vital status (dead or alive), date of death, and residence for all cancer patients.
Statistical analysis
We followed each patient from date of cancer diagnosis until emigration, death, or June 25, 2010, whichever came first. To visualize crude survival we constructed KaplanMeier curves, stratified according to period of diagnosis (1998-2000, 2001-2003, 2004-2006, and 2007-2009 ). We estimated 1-, 3-, and 5-year survival. In the latter periods we estimated 3-and 5-year survival using a hybrid analysis in which we included the actual survival for as long as possible and then estimated the conditional probability of surviving thereafter based on the corresponding survival experience of patients in the previous period (ie, using a period analysis technique). 19 To compare all-cause mortality over time, we used Cox proportional hazard regression analysis, with 1998-2000 as the reference period to estimate 1-, 3-, and 5-year mortality rate ratios (MRRs) and corresponding 95% confidence intervals (CIs), adjusting for age group (15-49 years, 50-74 years, and .75 years).
Analyses were performed using SAS (v 9.2; SAS Institute, Inc, Cary, NC).
Results
A total of 13,756 women had incident breast cancer during the period 1998-2009, with a median age of 62 years (range 21-102 years). The descriptive data are presented in Table 1 and Figure 1 .
The annual number of women with incident breast cancer nearly doubled in the end of our study period, from a total of 962 in 1998 to 1758 in 2009. In 1998-2006, around 58% of newly diagnosed breast cancer patients were in the age group 50-74 years. However, in 2007-2009, women aged 50-74 years constituted 70.1% of all newly diagnosed breast cancer patients (see Table 2 ). (Table 2 ). In women aged 15-49 years and more than 75 years both 1-and 5-year survival remained virtually unchanged during the study period; in the youngest women, the 1-year survivals were 97.0%-97.9%, and 5-year survival/predicted survivals were 86.6%-87.6%. In the elderly, the 1-year survival was 81.3%-81.1%, and 5-year survival was 46.5%-45.9% (Table 2) .
Discussion
In this population-based cohort study including nearly 14,000 breast cancer patients diagnosed between 1998 and 2009, we found that survival after breast cancer diagnosis gradually increased over the entire period. The 1-year mortality decreased more than 30%, and the 5-year mortality was submit your manuscript | www.dovepress.com
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Lietzen et al predicted to decrease by 20%. In the end of our study period, however, the annual number of women diagnosed with breast cancer nearly doubled.
The main strength of our study is the population-based design with a well defined catchment area and virtually complete follow-up, which minimizes the potential for selection bias. The use of data from the DNRP allowed for analyses updated to recent calendar years; however, the codes from the DNRP may not be entirely accurate. A previous Danish study conducted in northern Denmark compared ovarian cancer diagnoses recorded in the DNRP with similar data from the Danish Cancer Registry. The completeness of ovarian cancer diagnoses in the DNRP was 96%, and the positive predictive value was 87%. 20 Thus, we cannot rule out some misclassification of our patients, and if the positive predictive value increased over the study period this may have influenced our estimates. However, we find it likely that women without a breast cancer diagnosis have a better survival than women with a breast cancer diagnosis. Therefore, we do expect improved predictive values to result in decreased survival. Our study has other limitations worth addressing. We do not have information on cancer stage, tumor size, hormone receptor status, choice of medical treatment, comorbidity, or lifestyle; all of which have an impact on breast cancer outcome. 12, 21 Mortality trends among younger women with breast cancer could likely almost entirely be driven by breast cancer and its treatment, while mortality among older women is probably influenced by comorbidity. The improved survival among 50-74-year-old women in our study could thus to some extent be explained by improved survival in this age category in the general population. We are, however, unable to address the impact of these factors on the change we observed in breast cancer survival.
The weakness of the hybrid analysis design is that it may not be as accurate as directly observed survival. However, since we based our predictions on the survival experience in the previous period of our study, we expect our predictions to be conservative estimates of the increased survival among women with breast cancer.
Our finding of an improved breast cancer survival in central and northern Denmark extends the findings by Coleman et al 3 
39
Breast cancer survival in Denmark in the latest period may be affected by length time bias. 22 Since the aim of screening is to detect cancers at an earlier stage, 16 survival will also be prolonged even without change in time of death (lead time bias). However, we also observed improvement in survival before the screening program was implemented. Thus other factors must be involved.
The technical quality of diagnostic imaging with digital mammography, high resolution ultrasound, stereotactic biopsies, and adjunct MRI mammography has improved over the years [23] [24] [25] [26] so cancers could be detected at an earlier stage, even before the introduction of the screening program.
However, the treatment of breast cancer in Denmark during our study period has changed towards treatment by specialized breast surgeons working in multidisciplinary teams in centralized units with a higher volume of patients than just a few years ago. 27 This specialization might have contributed to the improved survival. 9 More widespread use of standardized treatment following the DBCG protocols may also have had an important impact on the improved survival. 12 These treatment changes include extended indications of adjuvant treatment with chemotherapy, endocrine treatment, biological treatment, and radiation therapy for smaller tumors, lower disease grades, and different age categories. 8 In conclusion, survival among breast cancer patients has improved in Denmark over the time period 1998-2009, and this change was most pronounced in women aged 50-74 years. Introduction of a screening program in the last part of our study period might have contributed to these findings, but improvement of survival was also observed in the first part of our study period before the screening program was implemented. This could thus reflect changes in adjuvant treatment. 
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